The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
AMBRX BIOPHARMA INC | SPONSORED ADS | 02290A102 | 17,216,790 | 7,584,489 | SH | SOLE | 7,584,489 | 0 | 0 | ||
ARGENX SE | SPONSORED ADR | 04016X101 | 112,778,070 | 297,701 | SH | SOLE | 297,701 | 0 | 0 | ||
KEROS THERAPEUTICS INC | COM | 492327101 | 20,578,107 | 428,532 | SH | SOLE | 428,532 | 0 | 0 | ||
PROMETHEUS BIOSCIENCES INC | COM | 74349U108 | 10,051,690 | 91,379 | SH | SOLE | 91,379 | 0 | 0 |